{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:13:00Z","timestamp":1791475980211,"version":"4.3.4"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>\n                      Patients with inflammatory bowel disease (IBD) to be treated with thiopurines should undergo preemptive genotyping for reduced-function thiopurine methyltransferase (\n                      <jats:italic toggle=\"yes\">TPMT<\/jats:italic>\n                      ) polymorphisms. Therapeutic drug monitoring (TDM) is recommended in cases of toxicity or a lack of efficacy. The relationship between\n                      <jats:italic toggle=\"yes\">TPMT<\/jats:italic>\n                      genotype and 6-thioguanine nucleotide (6-TGN) and 6-methylmercaptopurine (6-MMP) concentrations in the early steady state was assessed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      Consecutive adults with IBD to be treated with azathioprine underwent preemptive\n                      <jats:italic toggle=\"yes\">TPMT<\/jats:italic>\n                      genotyping and were dosed accordingly. All patients underwent TDM after 4\u20136 weeks of treatment and occasionally thereafter.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Of the 235 included patients, 45 were not genotyped for various reasons (45 samples at first TDM, 66 overall). Of the 190 patients who were genotyped, 19 (10%) were heterozygous (*1\/*3) (19 samples at first TDM, 32 overall) and 171 (90%) were wild-type (171 samples at first TDM, 280 overall). At first TDM, 7 patients were hypermethylators, and 6 were identified at later TDMs. Compared with patients with a wild-type genotype or those who were not genotyped, those who were heterozygous consistently had markedly higher 6-TGN (2-fold, 3.7-fold if dose-adjusted) and lower 6-MMP (75%\u201390%, 30%\u201350% if dose-adjusted) concentrations (pmol\/8 \u00d7 10\n                      <jats:sup>8<\/jats:sup>\n                      red blood cells). Based on the 6-TGN\/6-MMP profiles, they were 2\u20133 times less likely to be classified as receiving \u201ctoo low of a dose\u201d (6-TGN &lt;235 and 6-MMP &lt;5700 pmol\/8 \u00d7 10\n                      <jats:sup>8<\/jats:sup>\n                      red blood cells), and 4\u201320 times more likely to be classified as receiving \u201ctoo high of a dose\u201d (6-TGN &gt;450).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>\n                      These data support the importance of\n                      <jats:italic toggle=\"yes\">TPMT<\/jats:italic>\n                      genotyping and suggest that thiopurine TDM generates supplementary information and should be performed for all patients.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001327","type":"journal-article","created":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T14:54:16Z","timestamp":1743346456000},"page":"676-681","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Therapeutic Drug Monitoring of Thiopurines in Patients With Inflammatory Bowel Disease: Observations From Daily Practice"],"prefix":"10.1097","volume":"47","author":[{"given":"Mila","family":"Lovri\u0107","sequence":"first","affiliation":[{"name":"Department of Laboratory Diagnostics, University Hospital Centre Zagreb, Zagreb, Croatia;"},{"name":"Faculty of Pharmacy and Biochemistry, University of Zagreb, Zagreb, Croatia;"},{"name":"School of Medicine, University of Zagreb, Zagreb, Croatia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Duki\u0107","sequence":"additional","affiliation":[{"name":"Department of Laboratory Diagnostics, University Hospital Centre Zagreb, Zagreb, Croatia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvija","family":"\u010cukovi\u0107-\u010cavka","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Zagreb, Zagreb, Croatia;"},{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine, University Hospital Centre Zagreb, Zagreb, Croatia; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lana","family":"Ganoci","sequence":"additional","affiliation":[{"name":"Department of Laboratory Diagnostics, University Hospital Centre Zagreb, Zagreb, Croatia;"},{"name":"Department of Pharmacology, Zagreb University School of Medicine, Zagreb, Croatia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nada","family":"Bo\u017eina","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Zagreb University School of Medicine, Zagreb, Croatia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Trkulja","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Zagreb University School of Medicine, Zagreb, Croatia."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,3,28]]},"reference":[{"key":"R1-20250912","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/ecco-jcc\/jjw168","article-title":"3rd European evidence-based consensus on the diagnosis and management of Crohn's disease 2016: part 1: diagnosis and medical management","volume":"11","author":"Gomoll\u00f3n","year":"2017","journal-title":"J Crohns Colitis"},{"key":"R2-20250912","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1093\/ecco-jcc\/jjx009","article-title":"Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: current management","volume":"11","author":"Harbord","year":"2017","journal-title":"J Crohns Colitis"},{"key":"R3-20250912","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1093\/ecco-jcc\/jjx181","article-title":"Thiopurines in inflammatory bowel disease: new findings and perspectives","volume":"12","author":"de Boer","year":"2018","journal-title":"J Crohns Colitis"},{"key":"R4-20250912","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.3389\/fphar.2018.01107","article-title":"Revisiting the role of thiopurines in inflammatory bowel disease through pharmacogenomics and use of novel methods for therapeutic drug monitoring","volume":"9","author":"Lim","year":"2018","journal-title":"Front Pharmacol"},{"key":"R5-20250912","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1111\/bcp.12226","article-title":"Implementation of TPMT testing","volume":"77","author":"Lennard","year":"2014","journal-title":"Br J Clin Pharmacol"},{"key":"R6-20250912","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1586\/17474124.2014.894878","article-title":"The role of thiopurine metabolite monitoring in inflammatory bowel disease","volume":"8","author":"Beswick","year":"2014","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"R7-20250912","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/clpt.2010.320","article-title":"Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing","volume":"89","author":"Relling","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"R8-20250912","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.jmoldx.2022.06.007","article-title":"TPMT and NUDT15 genotyping recommendations: a joint consensus recommendation of the Association for Molecular Pathology, Clinical Pharmacogenetics Implementation Consortium, College of American Pathologists, Dutch Pharmacogenetics Working Group of the Royal Dutch Pharmacists Association, European Society for Pharmacogenomics and Personalized Therapy, and Pharacogenomics knowledge base","volume":"24","author":"Pratt","year":"2022","journal-title":"J Mol Diagn"},{"key":"R9-20250912","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1053\/j.gastro.2017.07.032","article-title":"American Gastroenterological Association Institute Guideline on therapeutic drug monitoring in inflammatory bowel disease","volume":"153","author":"Feuerstein","year":"2017","journal-title":"Gastroenterology"},{"key":"R10-20250912","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1111\/j.1365-2036.2008.03788.x","article-title":"Prospective evaluation of the pharmacogenetics of azathioprine in the treatment of inflammatory bowel disease","volume":"28","author":"Ansari","year":"2008","journal-title":"Aliment Pharmacol Ther"},{"key":"R11-20250912","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/S0016-5085(00)70354-4","article-title":"Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy","volume":"118","author":"Colombel","year":"2000","journal-title":"Gastroenterology"},{"key":"R12-20250912","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/ijcp.12039","article-title":"The impact of introducing thioguanine nucleotide monitoring into an inflammatory bowel disease clinic","volume":"67","author":"Smith","year":"2013","journal-title":"Int J Clin Pract"},{"key":"R13-20250912","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1136\/flgastro-2016-100738","article-title":"A practical guide to thiopurine prescribing and monitoring in IBD","volume":"9","author":"Warner","year":"2018","journal-title":"Frontline Gastroenterol"},{"key":"R14-20250912","doi-asserted-by":"crossref","first-page":"11","DOI":"10.5217\/ir.2020.00155","article-title":"Use of thiopurines in inflammatory bowel disease: an update","volume":"20","author":"Singh","year":"2022","journal-title":"Intest Res"},{"key":"R15-20250912","first-page":"16","article-title":"An epidemiological study of thiopurine-methyltransferase variants in a Croatian inflammatory bowel disease patient cohort","volume":"55","author":"Ladi\u0107","year":"2016","journal-title":"Acta Clin Croat"},{"key":"R16-20250912","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1093\/clinchem\/44.3.551","article-title":"Simultaneous determination of 6-thioguanine and methyl 6-mercaptopurine nucleotides of azathioprine in red blood cells by HPLC","volume":"44","author":"Dervieux","year":"1998","journal-title":"Clin Chem"},{"key":"R17-20250912","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1080\/01621459.2015.1023805","article-title":"Stable weights that balance covariates for estimation with incomplete outcome data","volume":"110","author":"Zubizarreta","year":"2015","journal-title":"J Am Stat Assoc"},{"key":"R20-20250912","doi-asserted-by":"crossref","first-page":"268","DOI":"10.7326\/M16-2607","article-title":"Sensitivity analysis in observational research: introducing the E-value","volume":"167","author":"VanderWeele","year":"2017","journal-title":"Ann Intern Med"},{"key":"R21-20250912","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1097\/FTD.0000000000000455","article-title":"Analytical pitfalls of therapeutic drug monitoring of thiopurines in patients with inflammatory bowel disease","volume":"39","author":"Simsek","year":"2017","journal-title":"Ther Drug Monit"},{"key":"R22-20250912","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s10620-022-07556-y","article-title":"Proactive metabolite testing in patients on thiopurine may yield long-term clinical benefits in inflammatory bowel disease","volume":"68","author":"Barnes","year":"2023","journal-title":"Dig Dis Sci"},{"key":"R23-20250912","doi-asserted-by":"crossref","first-page":"3296","DOI":"10.1111\/bcp.16219","article-title":"Early therapeutic drug monitoring helps to identify inflammatory bowel disease patients with a high risk to fail thiopurine treatment","volume":"90","author":"Deben","year":"2024","journal-title":"Br J Clin Pharmacol"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001327","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T12:02:22Z","timestamp":1757678542000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001327"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,28]]},"references-count":21,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001327","relation":{},"ISSN":["0163-4356","1536-3694"],"issn-type":[{"value":"0163-4356","type":"print"},{"value":"1536-3694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,28]]},"assertion":[{"value":"2024-10-01","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-13","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}